Nowadays the Borderline Personality Disorder (BPD) lacks any treatment with administrative approval. International prestige guidelines accept the generalized use of atypical antipsychotics by clinicians for this disorder, including quetiapine.

To evaluate the clinical effect of Quetiapine in the treatment of BPD and the patient's perception of this treatment.

Multi-center, naturalistic, retrospective study. Patients over 18 with BPD diagnoses (DSM-IV-TR) in treatment with quetiapine for the previous 6 months were included. Assessments: CGI-C (Clinical Global Impression of Change), DAI-10 (Drug Attitude Inventory, 10 item) and a likert scale measuring the patient's subjective compliance.

105 patients were included. Mean age was 35.25±9.68 years old. 53.3% were male. Mean dose of Quetiapine was 422.06 mg/day (SD:171.42). The CGI-C results showed that 94.3% of the patients improved along the previous 6 months in treatment with quetiapine; 5,7% had no changes and 0% impaired. According to the DAI-10 results most of the patients thought good things about medication outweighed the bad (82,9%), took medication of their own free choice (72,4%) and associated treatment with breakdowns prevention (75.2%). Regarding to the perception of quetiapine most of the patients felt more relaxed (89.5%), with clearer thoughts (62.9%) and didn't associate treatment with sluggishness (62.9%) or strangeness and doping-up (74.3%). 96.1% of the patients reported compliance over 70%.

Clinicians found quetiapine effective for treating BPD and most of the patients perceived it positively and showed high levels of compliance